More From Employee Benefit News
Employers face a new GLP-1 question: Are the drugs worth it?
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
What Trump’s ‘Great Healthcare Plan’ means for drug costs and price transparency
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
Healthcare costs are forcing employers to reconsider their benefits strategy
Employers are under pressure to keep benefits competitive while controlling costs, driving new scrutiny of PBMs, hospital prices and GLP-1 coverage for 2027.
Benefits Think Preparing benefits for the next wave: Gene therapy medications
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
Benefits Think PBM playbook, part 2: Changes to the market and the value of a pharmacy benefits expert
A look at traditional PBMs and pass-through models, potential savings areas, developments and partnering with the right consultant.
